🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At 22 years old, did you know that PBTC (who we love!), is one of the strongest NCI founded consortiums focused on improving the treatment of pediatric brain tumors?

PBTC represents 15 top pediatric brain tumor hospitals in the US and Canada! Children's Hospital LA Stanford Children's Children's Hospital Colorado Foundation Children's National Hospital 🏥 The Women's and Children's Center Lurie Children's Dana-Farber @sloan_kettering Cincinnati Children's Nationwide Children's Hospital The Hospital for Sick Children (SickKids) UPMC Children's Hospital of Pittsburgh St. Jude Texas Children's

Great research at work! pubmed.ncbi.nlm.nih.gov/33631016/ "Over 70% of children with recurrent optic pathway/hypothalamic low-grade glioma had shrinkage or stability of their tumor using selumetinib (an oral agent)."

Getting ready for our 2021 PBTC Spring Virtual Meeting this Monday. Excited to get updates on many great trials!

To date, 41 clinical trials have been completed by PBTC, benefiting over 1900 children fighting brain tumors.

Now you can get daily updates on new PBTC trials with our new trial finder at pbtcf.org!

PBTC isn't just about research; it's about strategy. We use 5 main cores (biostatistics, imaging, pharma, genomics and pathology) to enhance every trial we implement.

Trial Alert: PBTC-055 Phase I trial for BRAF or NF1 gliomas in children and young adults is enrolling. This combination harnesses some laboratory work that shows that the addition of the agent HCQ may help overcome the resistance that tumors develop to these targeted therapies.

Trial Alert: PBTC-053 Phase I&II trial for recurrent SHH Medulloblastoma is accruing. CX-4945 is an oral agent that inhibits CK2, an important key to tumor propagation.

Trial Alert: 5.PBTC-051 Phase I Study to evaluate CD40 with pediatric recurrent/refractory brain tumors and newly diagnosed brain stem glioma has slots available. This agent promotes CD40 which is an important regulator of the body’s immune system attack on tumor cells.

Trial Alert: PBTC-047 by Dr. Michelle Monje-Deisseroth for a Phase I Trial of Panobinostat in Children with DIPG. This trial harnesses our understanding of the biology of DIPG to attack the tumor. Accrual ongoing with study completion soon.

1.PBTC-045: A trial of MK-3475 in children with recurrent, progressive or refractory HGG, ependymoma and medulloblastoma is now recruiting. This is an agent that helps activate the body’s own immune system to attack tumor. See our trial finder at pbtcf.org

PBTC and PBTCF congratulates Dr. Michelle Monje-Deisseroth Michelle Monje🎗️ 🟦 for being selected as an HHMI investigator (hhmi.org) and as a MacArthur Fellow! (macfound.org/programs/fello…)

PBTC and PBTCF celebrates Dr. Eric Bouffet’s selection as the 2021 recipient of the SNO Lifetime Achievement Award! (soc-neuro-onc.org/WEB/About_Cont…)

Phase update: PBTC-055 (Lindsey Hoffman, PI) has established the recommended dose and is now enrolling LGGs with BRAF-fusion or NF-1 in Phase 2 (clinicaltrials.gov/ct2/show/recor…)

The PBTC 2022 Fall Meeting has commenced! Welcome everyone, it's going to be a great day in Memphis #PBTCFallMeeting2022

We are #Hiring! Apply today to join the PBTC at St. Jude Children's Research Hospital as a Data Engineer/Data Engineer II/Sr. Data Engineer (remote/hybrid/on campus) talent.stjude.org/careers/jobs/1… #jobs #remotejobs #remotework #dataengineer #csharp #programming #sqlserver

Successful Spring 2024 meeting in Albuquerque! Celebrating 25 years of PBTC's vital role in advancing pediatric brain tumor research, thanks to the NCI. Gratitude to all attendees for their contributions!

See the recent update from Dr. Fangusaro of the Pediatric Brain Tumor Consortium and how new innovative research at leading North American hospitals is helping us find the cure for pediatric brain cancers. Learn more: youtu.be/7ne_fIpo2X4